TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia.

Choi YJ, Kim J, Mai XL, de Guzman ACV, An YJ, Kim HS, Cho BS, Park S

DOI: 10.3389/fonc.2026.1926332
Published: 2026
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1926332,
  title = {TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia.},
  author = {Choi YJ and Kim J and Mai XL and de Guzman ACV and An YJ and Kim HS and Cho BS and Park S},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1926332},
  url = {https://doi.org/10.3389/fonc.2026.1926332}
}

RIS

TY  - JOUR
TI  - TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia.
AU  - Choi YJ
AU  - Kim J
AU  - Mai XL
AU  - de Guzman ACV
AU  - An YJ
AU  - Kim HS
AU  - Cho BS
AU  - Park S
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1926332
UR  - https://doi.org/10.3389/fonc.2026.1926332
ER  -

APA

YJ, C., J, K., XL, M., ACV, D. G., YJ, A., HS, K., BS, C., & S, P. (2026). TMEM150C and F2R as transcriptomic signatures for refractoriness to 7 + 3 induction therapy in acute myeloid leukemia.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1926332

Source records

pubmed · retrieved 2026-11-10T10:34:31.995Z